|Mr. Anthony S. Marucci||Founder, Pres, CEO & Director||916.54k||N/A||1962|
|Dr. Tibor Keler||Founder, Chief Scientific Officer & Exec. VP||578.63k||N/A||1959|
|Mr. Sam Martin||Sr. VP, CFO, Sec. & Treasurer||449.99k||N/A||1971|
|Ms. Elizabeth Crowley||Chief Product Devel. Officer & Sr. VP||454.87k||N/A||1972|
|Dr. Margo Heath-Chiozzi M.D.||Sr. VP of Regulatory Affairs||482.83k||N/A||1957|
Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of immunotherapies and other cancer-targeting biologics. It develops CDX-1140, an agonist human monoclonal antibody, currently being studied as a single-agent and in combination with CDX-301 in a Phase I dose-escalation study in multiple types of solid tumors and B cell lymphomas; CDX-3379, a human monoclonal antibody designed to block the activity of ErbB3 that is in an early Phase II study in advanced head and neck squamous cell cancer in combination with Erbitux; CDX-301, a dendritic cell growth factor; and Varlilumab, an immune modulating antibody targeting CD27 designed to enhance a patient's immune response. Celldex Therapeutics, Inc. has research collaboration and license agreements with Medarex, Inc.; University of Southampton; Amgen Inc.; Yale University; and MedImmune, LLC. The company is headquartered in Hampton, New Jersey.
Celldex Therapeutics, Inc.’s ISS Governance QualityScore as of July 29, 2019 is 3. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 1; Compensation: 7.